Genmab — December 2019
-
-
Summary points from expert feedback:
Results are early but encouraging, with Celgene’s CC-93269 being slightly more impressive thanks to there being more data available
Convenience, flexibility and potency suggest bispecifics have first-line potential
First bispecific approved could have an important commercial advantage -
God morgen.
-
FirstWord: How competitive does GlaxoSmithKline’s belantamab mafodotin (formerly known as GSK2857916) look and is there a niche that the antibody-drug conjugate could fill or is it likely to be made obsolete by CAR-T and/or bispecific antibodies?
“The efficacy was a little lower than I expected so that is a little disappointing and it does not look competitive with CAR-T or bispecifics, plus the ocular toxicity is going to be a major problem.”
-
JNJ prøver at placere deres CAR-T i relapsed/refrac mm https://clinicaltrials.gov/ct2/show/NCT04181827?term=BCMA+daratumumab&draw=2&rank=1
-
-
Glædelig Jul til alle her på Proinvestors Genmab-chat
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind